News from astellas pharma europe limited A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

24 Mar, 2015, 11:23 GMT Astellas Announces New Enzalutamide Data Presented During Plenary Presentations at the 2015 European Association of Urology Congress

Astellas Pharma Europe Ltd. today announced new data from the Phase 2 TERRAIN trial of enzalutamide compared to bicalutamide in metastatic...


23 Sep, 2011, 16:17 BST CHMP Recommends Astellas Pharma Europe Ltd.'s (APEL) DIFICLIR™ for Approval in the EU

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for...


23 Sep, 2011, 14:47 BST CHMP Recommends Astellas Pharma Europe Ltd.'s (APEL) DIFICLIR™ for Approval in the EU

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Committee for Medicinal Products for...


21 Sep, 2011, 15:58 BST World-leading Biomedical Engineer, Dr Robert Langer, to Receive Economist Innovation Award Sponsored by Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd. announced today that one of the world's most influential biomedical engineers, Dr Robert Langer - the man responsible for ...


05 Sep, 2011, 17:41 BST El estudio Osaka mostró una eficacia similar para ADVAGRAF™ y PROGRAF™

- El estudio Osaka evaluó una población de transplante europea típica y mostró una eficacia similar para ADVAGRAF™ y PROGRAF™ en transplante renal en ...


05 Sep, 2011, 13:29 BST The Osaka Study Evaluated a Typical European Transplant Population and Showed Similar Efficacy for ADVAGRAF™ and PROGRAF™ in Renal Transplantation at the Same 0.2MG/KG Starting Dose

- Optimizing ImmunoSuppression After Kidney Transplantation with ADVAGRAF (OSAKA) study results presented at the European Society for Organ...


01 Sep, 2011, 08:30 BST Astellas Employees Walk 500 Million Steps to Reach Corporate Health Milestone

Employees at Astellas Pharma Europe Ltd. have given themselves a major summer health boost by walking more than 500 million steps - the equivalent of ...


28 Feb, 2011, 13:06 GMT Peripheral Neuropathic Pain Patients in Sweden set to Benefit From First-of-a-Kind Treatment Which Provides Lasting Pain Relief

- Decision to Reimburse Qutenza(TM) (capsaicin 8% w/w dermal patch) by Sweden's Dental and Pharmaceutical Benefits Agency (Tand-och...